Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opexa Therapeutics (OPXA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,741
  • Shares Outstanding, K 7,660
  • Annual Sales, $ 2,910 K
  • Annual Income, $ -7,980 K
  • 36-Month Beta 2.12
  • Price/Sales 2.35
  • Price/Cash Flow 0.00
  • Price/Book 3.04
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/10/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.60 +46.67%
on 06/28/17
1.45 -39.31%
on 07/05/17
+0.26 (+41.94%)
since 06/27/17
3-Month
0.55 +60.00%
on 06/22/17
1.45 -39.31%
on 07/05/17
+0.20 (+29.41%)
since 04/27/17
52-Week
0.50 +76.00%
on 11/15/16
4.93 -82.15%
on 08/24/16
-3.34 (-79.15%)
since 07/27/16

Most Recent Stories

More News
Company News for July 05, 2017

Companies in the News are: RATE,EQT,MSDI,OPXA

RATE : 13.90 (+0.36%)
EQT : 67.02 (+4.77%)
OPXA : 0.88 (-1.12%)
MSDI : 0.64 (-1.54%)
Featured Company News - Opexa Therapeutics and Acer Therapeutics Announced Merger Agreement Followed by Concurrent Financing from Acer Investor Syndicate

Research Desk Line-up: Neptune Technologies & Bioressources Post Earnings Coverage

OPXA : 0.88 (-1.12%)
NEPT : 0.87 (-3.33%)
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

CARA : 13.94 (-4.39%)
BMRN : 87.32 (-2.11%)
ACOR : 21.70 (-3.77%)
ALKS : 54.90 (-4.64%)
AMGN : 172.15 (-2.13%)
BIIB : 287.95 (-2.59%)
OPXA : 0.88 (-1.12%)
Today's Research Reports on Stocks to Watch: Opexa Therapeutics and Prana Biotechnology

NEW YORK, NY / ACCESSWIRE / July 5, 2017 / Shares of both Opexa Therapeutics and Prana Biotechnology saw a big trading day on Monday. Opexa shares exploded after traders found out that the company would...

PRAN : 2.73 (-4.70%)
OPXA : 0.88 (-1.12%)
Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement

Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need

OPXA : 0.88 (-1.12%)
Opexa Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

THE WOODLANDS, TX / ACCESSWIRE / May 12, 2017 / Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today reported financial...

OPXA : 0.88 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a...

See More

Support & Resistance

2nd Resistance Point 0.93
1st Resistance Point 0.90
Last Price 0.88
1st Support Level 0.86
2nd Support Level 0.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.